Trump signs psychedelic research order

In a significant shift in federal drug policy, the White House has directed health authorities to expedite the review of substances such as ibogaine, psilocybin, and LSD. The executive order aims to provide new therapeutic options for military veterans, many of whom have reported life-changing results from psychedelic treatments.

While the initiative has received support from mental health advocates, some medical experts have warned about the potential heart risks associated with certain plant-based psychedelics.

The policy change marks a rare point of intersection between the administration and figures in the alternative media landscape.